PCSANEG Stock Latest News
Private CompaniesSanegeneBio Reports Positive Interim Phase 2 Data for Kidney RNAi Therapy1w agoSANEG
Private CompaniesSanegeneBio Highlights Interim Phase 2 Kidney-Disease Data for RNAi Therapy2w agoSANEG
Private CompaniesSanegeneBio Showcases RNAi Delivery Platform at RNALeaders USA Congress1M agoSANEG
Private CompaniesSanegeneBio to Present RNAi Pipeline Updates at Major Healthcare Conference1M agoSANEG- Private CompaniesSanegeneBio Strengthens Leadership to Advance RNAi Drug Development2M agoSANEG
Private CompaniesSanegeneBio – Weekly Recap5M agoSANEG
Private CompaniesSanegeneBio Gains NMPA Clearance to Advance SGB-9768 in Hematologic Indications5M agoSANEG
Private CompaniesSanegeneBio to Spotlight RNAi Obesity Program and Delivery Platform at TIDES USA 20266M agoSANEG
Private CompaniesSanegeneBio Highlights RNAi Obesity Program Ahead of TIDES USA 20266M agoSANEG
Private CompaniesSanegeneBio Showcases RNAi Obesity Program and Delivery Platform at TIDES USA6M agoSANEG- Private CompaniesSanegeneBio Highlights siRNA Platform and CMC Capabilities at OPT Congress7M agoSANEG
Private CompaniesSanegeneBio Highlights siRNA Platform and CMC Capabilities at OPT Congress7M agoSANEGPrivate CompaniesSanegeneBio Highlights RNAi Pipeline Progress in Rare and Complement-Mediated Diseases8M agoSANEG
Private CompaniesSanegeneBio Secures $200 Million Upfront in Global RNAi Licensing Deal With Genentech8M agoSANEG